Anti‑inflammatory effects of escin are correlated with the glucocorticoid receptor/NF‑κB signaling pathway, but not the COX/PGF2α signaling pathway

Wang,Hongsheng; Zhang,Leiming; Jiang,Na; Wang,Zhenhua; Chong,Yating; Fu,Fenghua

doi:10.3892/etm.2013.1128

Anti‑inflammatory effects of escin are correlated with the glucocorticoid receptor/NF‑κB signaling pathway, but not the COX/PGF2α signaling pathway

Authors:
- Hongsheng Wang
- Leiming Zhang
- Na Jiang
- Zhenhua Wang
- Yating Chong
- Fenghua Fu
View Affiliations

Affiliations: Department of Pharmacology, School of Pharmacy, Yantai University, Yantai, Shandong 264005, P.R. China
Published online on: May 22, 2013 https://doi.org/10.3892/etm.2013.1128
Pages: 419-422

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In China, escin has been widely used in the clinic as a potent anti‑inflammatory drug. Previous studies have indicated that escin exerts its anti-inflammatory effect by enhancing the release of glucocorticoids (GCs) and prostaglandin‑F2α (PGF2α), and this has been documented in the drug description. However, our previous studies demonstrated that escin did not increase the secretion of GCs, but instead elevated the protein expression of the GC receptor (GR), which may have repressed nuclear factor (NF)‑κB‑mediated gene expression. The aim of this study was to determine the functions of NF‑κB and PGF2α with regard to the anti‑inflammatory effect of escin. We investigated the anti‑inflammatory effects of dexamethasone, diclofenac and escin against carrageenan‑induced paw edema in rats, and observed that escin exerted a GC‑like anti‑inflammatory effect. In addition, we studied the role of PGF2α in the anti‑inflammatory effect exerted by escin in an acetic acid‑induced capillary permeability model in mice. The results revealed that the coadministration of escin and diclofenac, a potent prostaglandin‑synthesis inhibitor, did not affect the anti‑inflammatory effect of escin. Furthermore, we investigated the function of NF‑κB with regard to the anti‑inflammatory effect exerted by escin in lipopolysaccharide (LPS)‑treated mice, and demonstrated that escin significantly inhibited the expression of NF‑κB. These results suggest that escin has a GC‑like anti‑inflammatory effect, and that its mechanisms may be correlated with the GC receptor/NF‑κB signaling pathway, but not the COX/PGF2α signaling pathway.

View Figures

View References

1.	Fu F, Hou Y, Jiang W, Wang R and Liu K: Escin: inhibiting inflammation and promoting gastrointestinal transit to attenuate formation of postoperative adhesions. World J Surg. 29:1614–1620. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Zhang L, Fu F, Zhang X, Zhu M, Wang T and Fan H: Escin attenuates cognitive deficits and hippocampal injury after transient global cerebral ischemia in mice via regulating certain inflammatory genes. Neurochem Int. 57:119–127. 2010. View Article : Google Scholar
3.	Xin W, Zhang L, Fan H, Jiang N, Wang T and Fu F: Escin attenuates acute lung injury induced by endotoxin in mice. Eur J Pharm Sci. 42:73–80. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Jiang N, Xin W, Wang T, Zhang L, Fan H, Du Y, Li C and Fu F: Protective effect of aescin from the seeds of Aesculus hippocastanum on liver injury induced by endotoxin in mice. Phytomedicine. 18:1276–1284. 2011. View Article : Google Scholar : PubMed/NCBI
5.	Zhang L, Wang H, Fan H, Wang T, Jiang N, Yu P and Fu F: The potent anti-inflammatory agent escin does not increase corticosterone secretion and immune cell apoptosis in mice. Fitoterapia. 82:861–867. 2011. View Article : Google Scholar : PubMed/NCBI
6.	Rhen T and Cidlowski JA: Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med. 353:1711–1723. 2005. View Article : Google Scholar : PubMed/NCBI
7.	Wang YW, Wang SJ, Zhou YN, Pan SH and Sun B: Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo. J Cancer Res Clin Oncol. 138:785–797. 2012.PubMed/NCBI
8.	Harikumar KB, Sung B, Pandey MK, Guha S, Krishnan S and Aggarwal BB: Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Mol Pharmacol. 77:818–827. 2010. View Article : Google Scholar
9.	Williams PB and Joyner JH: Response of peripheral collateral arteries in the dog to prostaglandins E1, E2, F2 alpha, and I2 (prostacyclin). J Cardiovasc Pharmacol. 4:784–790. 1982. View Article : Google Scholar : PubMed/NCBI
10.	Emerson TE Jr, Jelks GW, Daugherty RM Jr and Hodgman RE: Effects of prostaglandin E1 and F2 alpha on venous return and other parameters in the dog. Am J Physiol. 220:243–249. 1971.PubMed/NCBI
11.	Uski TK, Andersson KE, Brandt L and Ljunggren B: Characterization of the prostanoid receptors and of the contractile effects of prostaglandin F2 alpha in human pial arteries. Acta Physiol Scand. 121:369–378. 1984. View Article : Google Scholar : PubMed/NCBI
12.	Amann-Vesti BR, Gitzelmann G, Koppensteiner R and Franzeck UK: Isoprostane 8-epi-prostaglandin F2 alpha decreases lymph capillary pressure in patients with primary lymphedema. J Vasc Res. 40:77–82. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Sinzinger H, Oguogho A and Kaliman J: Isoprostane 8-epi-prostaglandin F2 alpha is a potent contractor of human peripheral lymphatics. Lymphology. 30:155–159. 1997.PubMed/NCBI
14.	Longiave D, Omini C, Nicosia S and Berti F: The mode of action of aescin on isolated veins: relationship with PGF2 alpha. Pharmacol Res Commun. 10:145–152. 1978. View Article : Google Scholar : PubMed/NCBI
15.	Berti F, Omini C and Longiave D: The mode of action of aescin and the release of prostaglandins. Prostaglandins. 14:241–249. 1977. View Article : Google Scholar : PubMed/NCBI
16.	Carrasco OF and Vidrio H: Endothelium protectant and contractile effects of the antivaricose principle escin in rat aorta. Vascul Pharmacol. 47:68–73. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, et al: International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev. 58:782–797. 2006. View Article : Google Scholar
18.	Mckay LI and Cidlowski JA: Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocrine Rev. 20:435–459. 1999.
19.	Ku EC, Wasvary JM and Cash WD: Diclofenac sodium (GP 45840, Voltaren), a potent inhibitor of prostaglandin synthetase. Biochem Pharmacol. 24:641–643. 1975. View Article : Google Scholar : PubMed/NCBI
20.	Ku EC, Kothari H, Lee W, Kimble EF and Liauw LH: Effects of diclofenac sodium on arachidonic acid metabolism. Agents Actions Suppl. 17:189–193. 1985.PubMed/NCBI